253 related articles for article (PubMed ID: 31693922)
1. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.
Ricci-López J; Vidal-Limon A; Zunñiga M; Jimènez VA; Alderete JB; Brizuela CA; Aguila S
PLoS One; 2019; 14(3):e0213028. PubMed ID: 30875378
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of small molecule human papillomavirus E6 inhibitors.
Malecka KA; Fera D; Schultz DC; Hodawadekar S; Reichman M; Donover PS; Murphy ME; Marmorstein R
ACS Chem Biol; 2014 Jul; 9(7):1603-12. PubMed ID: 24854633
[TBL] [Abstract][Full Text] [Related]
4. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening for Potential Inhibitors of High-Risk Human Papillomavirus 16 E6 Protein.
Kumar S; Jena L; Mohod K; Daf S; Varma AK
Interdiscip Sci; 2015 Jun; 7(2):136-42. PubMed ID: 26199214
[TBL] [Abstract][Full Text] [Related]
6. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
7. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
8. A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells.
Messa L; Celegato M; Bertagnin C; Mercorelli B; Nannetti G; Palù G; Loregian A
Sci Rep; 2018 Apr; 8(1):6020. PubMed ID: 29662081
[TBL] [Abstract][Full Text] [Related]
9. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
10. Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.
Rietz A; Petrov DP; Bartolowits M; DeSmet M; Davisson VJ; Androphy EJ
PLoS One; 2016; 11(2):e0149845. PubMed ID: 26915086
[TBL] [Abstract][Full Text] [Related]
11. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
12. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
13. Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.
Bonetta AC; Mailly L; Robinet E; Travé G; Masson M; Deryckere F
Biochem Biophys Res Commun; 2015 Oct; 465(4):658-64. PubMed ID: 26241675
[TBL] [Abstract][Full Text] [Related]
14. Cellular binding partners of the human papillomavirus E6 protein.
Tungteakkhun SS; Duerksen-Hughes PJ
Arch Virol; 2008; 153(3):397-408. PubMed ID: 18172569
[TBL] [Abstract][Full Text] [Related]
15. An in silico appraisal of azoic and disulphide derivatives for anticancer activity against HPV E6 oncoprotein to medicate cervical cancer.
Choudhury AD; Choudhury MD; Chetia P; Chowdhury A; Talukdar AD
Comb Chem High Throughput Screen; 2014 Jan; 17(1):38-46. PubMed ID: 24164050
[TBL] [Abstract][Full Text] [Related]
16. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.
Ramirez J; Poirson J; Foltz C; Chebaro Y; Schrapp M; Meyer A; Bonetta A; Forster A; Jacob Y; Masson M; Deryckère F; Travé G
Angew Chem Int Ed Engl; 2015 Jun; 54(27):7958-62. PubMed ID: 26014966
[TBL] [Abstract][Full Text] [Related]
18. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis.
Braun JA; Herrmann AL; Blase JI; Frensemeier K; Bulkescher J; Scheffner M; Galy B; Hoppe-Seyler K; Hoppe-Seyler F
Int J Cancer; 2020 Jan; 146(2):461-474. PubMed ID: 31603527
[TBL] [Abstract][Full Text] [Related]
19. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
